Esperion Therapeutis.Inc. sell Northland Securities
Start price
16.03.23
/
50%
€1.91
Target price
16.03.24
-
Performance (%)
4.19%
End price
17.03.24
€1.99
Summary
This prediction ended on 17.03.24 with a price of €1.99. The SELL prediction by Northland_Securities shows the price for Esperion Therapeutis.Inc. slightly increased by 4.19% during the runtime of the prediction. Northland_Securities has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -7.041% | -7.041% | 103.136% | 52.014% |
| iShares Core DAX® | 0,79 % | 1,97 % | 13,39 % | 49,83 % |
| iShares Nasdaq 100 | 4,23 % | 4,34 % | 39,72 % | 89,76 % |
| iShares Nikkei 225® | 3,29 % | 6,99 % | 49,89 % | 64,38 % |
| iShares S&P 500 | 2,50 % | 2,76 % | 30,23 % | 64,25 % |
Comments by Northland_Securities for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von Northland_Securities gewählte maximale Laufzeit wurde überschritten